Piper Sandler analyst David Westenberg lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $85 following quarterly ...
Leerink Partners analyst Puneet Souda has maintained their bullish stance on EXAS stock, giving a Buy rating yesterday. Puneet Souda’s ...
--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present modeling data evaluating the simulated ...
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present modeling data evaluating the simulated benefit and burden ...
No teams are on bye this week. Before you make any Week 8 NFL picks, be sure to see the exact NFL score predictions from SportsLine expert Eric Cohen. Cohen, a SportsLine NFL expert and host of ...
October 27, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present modeling data ...
No teams are on bye this week. Before you make any Week 8 NFL picks, be sure to see the exact NFL score predictions from SportsLine expert Eric Cohen. Cohen, a SportsLine NFL expert and host of the ...
Wells Fargo has recently initiated Exact Sciences Corp (EXAS) stock to Overweight rating, as announced on August 28, 2024, according to Finviz. Earlier, on June 27, 2024, Scotiabank had initiated the ...
Exact Sciences EXAS is slated to report its third-quarter 2024 earnings on Nov. 5. Exact Sciences is a leading cancer diagnostics company, which focuses on the development of new and innovative ...